- Home
- ATOS vs CRBU Comparison
ATOS vs CRBU Comparison
Compare ATOS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CRBU
- Stock Information
- Founded
- ATOS 2009
- CRBU 2011
- Country
- ATOS United States
- CRBU United States
- Employees
- ATOS N/A
- CRBU N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ATOS Health Care
- CRBU Health Care
- Exchange
- ATOS Nasdaq
- CRBU Nasdaq
- Market Cap
- ATOS 112.5M
- CRBU 93.0M
- IPO Year
- ATOS 2012
- CRBU 2021
- Fundamental
- Price
- ATOS $0.85
- CRBU $1.38
- Analyst Decision
- ATOS Strong Buy
- CRBU Strong Buy
- Analyst Count
- ATOS 3
- CRBU 4
- Target Price
- ATOS $6.17
- CRBU $8.50
- AVG Volume (30 Days)
- ATOS 1.5M
- CRBU 1.8M
- Earning Date
- ATOS 08-11-2025
- CRBU 08-05-2025
- Dividend Yield
- ATOS N/A
- CRBU N/A
- EPS Growth
- ATOS N/A
- CRBU N/A
- EPS
- ATOS N/A
- CRBU N/A
- Revenue
- ATOS N/A
- CRBU $9,918,000.00
- Revenue This Year
- ATOS N/A
- CRBU $12.83
- Revenue Next Year
- ATOS N/A
- CRBU N/A
- P/E Ratio
- ATOS N/A
- CRBU N/A
- Revenue Growth
- ATOS N/A
- CRBU N/A
- 52 Week Low
- ATOS $0.55
- CRBU $0.66
- 52 Week High
- ATOS $1.66
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- ATOS 51.17
- CRBU 61.54
- Support Level
- ATOS $0.81
- CRBU $1.22
- Resistance Level
- ATOS $0.92
- CRBU $1.44
- Average True Range (ATR)
- ATOS 0.05
- CRBU 0.11
- MACD
- ATOS -0.00
- CRBU -0.00
- Stochastic Oscillator
- ATOS 52.73
- CRBU 82.50
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.